ELEV - Elevation Oncology, Inc. Stock Price, Fair Value and News

$0.37

Market Closed as of 01 Aug 2025, 04:00 pm ET

ELEV Stock Valuation Analysis

Valuation

Max Portfolio %

ELEV Price Action

ELEV RSI Chart

ELEV Stock Valuation Analysis

Valuation

Max Portfolio %

ELEV Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ELEV Fundamentals

ELEV Earnings

ELEV Profitability

ELEV Investor Care

Revenue & Growth

About Elevation Oncology, Inc.

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

CEO	Mr. Joseph J. Ferra Jr.
WEBSITE	https://elevationoncology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	33